Kodiak Sciences Inc.

What they do

Kodiak develops next-generation retinal medicines using its Antibody Biopolymer Conjugate (ABC) platform. Its lead candidates are tarcocimab tedromer (Zenkuda), an anti-VEGF therapy for retinal vascular diseases; KSI-501, a bispecific anti-IL-6/VEGF-trap; and KSI-101, a high-strength bispecific for macular edema secondary to inflammation. The company has completed four Phase 3 pivotal studies of Zenkuda and is enrolling or running additional Phase 3 trials across the portfolio. All operations are clinical-stage, with no commercial sales.

Revenue drivers

• Zenkuda (tarcocimab tedromer) — Lead anti-VEGF candidate for wet AMD, DME, DR, and RVO; completed Phase 3 studies and is being prepared for BLA submission; no revenue yet, but is the furthest along toward commercialization.
• KSI-501 — Bispecific anti-IL-6/VEGF-trap for wet AMD and DME; in Phase 3 DAYBREAK (wet AMD) and ALTO (DME); no revenue, potential future product.
• KSI-101 — High-strength bispecific targeting IL-6 and VEGF for macular edema secondary to inflammation (MESI); in Phase 3 PEAK and PINNACLE trials; no revenue, potential future product.

Recent performance

For Q2 2026, Kodiak reported net loss of $65.6 million ($1.05 per share) versus $54.3 million ($1.03 per share) in Q2 2025. R&D expenses rose to $56.1 million from $42.8 million, driven by higher clinical and manufacturing activity; G&A expenses fell to $10.8 million from $12.8 million. Cash and equivalents were $125.9 million as of June 30, 2026. Annual net losses from 2021 to 2025 ranged from $176.2 million (2024) to $333.8 million (2022).

Strategy

Management is focused on late-stage clinical execution and regulatory preparation, with three Phase 3 readouts targeted between September and December 2026. The company is advancing Zenkuda toward BLA submission while studying KSI-501 and KSI-101 in registrational trials. DAYBREAK is evaluating both Zenkuda and KSI-501 in wet AMD using an AI-driven dosing tool to support a flexible 1- to 6-month label. ALTO is designed to show KSI-501 superiority over aflibercept in DME. Kodiak expects current cash to fund operations into 2027.

Risks

• Clinical failure risk — Prior trials (DAZZLE, GLEAM, GLIMMER) failed to meet primary endpoints, and there is no guarantee that DAYBREAK, PEAK, or ALTO will succeed.
• Regulatory and labeling risk — The FDA may not approve the intended dosing label or may require separate review of the AI-based dosing tool used in DAYBREAK, potentially delaying or narrowing approval.
• Going concern and financing risk — The 10-K states that financial condition raises substantial doubt about ability to continue as a going concern, and additional financing may be needed to complete development.
• No revenue and limited operating history — The company has no approved products or revenue, and its prospects depend entirely on successful development and commercialization of three unapproved candidates.

Outlook

Management expects topline data for the DAYBREAK one-year primary endpoint (Zenkuda and KSI-501) in September 2026 and for PEAK Pivotal Analysis 1 (KSI-101) in December 2026. Enrollment for the second PEAK/PINNACLE cohort is expected to complete in Q4 2026, with topline data in Q2 2027. The company continues BLA preparation for Zenkuda and expects cash to support operations into 2027.